CymaBay Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/28/2024
CymaBay Therapeutics Stock Forecast and Price Target
If CymaBay Therapeutics's stock price reached the average yearlong target of $17.45 given by five well-known analysts in recent months, there would be a potential downside of approximately -46.21% from its last closing price in March, 2024. This potential increase is based on a high estimate of $19.55 and a low estimate of $15.53. If interested in CBAY stock, you may also want to consider its competitors.
-46.21% Downside
CymaBay Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, CymaBay Therapeutics's Price has grown by 100.00%, rising from $0.00 to $0.00. For the next year, analysts predict that Fair Value will reach $34.90 – an increase of 100.00%. Over the next seven years, experts believe that CymaBay Therapeutics's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$159.62 | Buy/Sell | $178.42 | 16.53% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$269.98 | Buy/Sell | $303.65 | 17.51% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.42 | Buy/Sell | $87.82 | 22.29% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$208.90 | Buy/Sell | $299.62 | 38.10% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$80.91 | Buy/Sell | $111.56 | 35.95% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$51.68 | Buy/Sell | $77.05 | 49.38% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$74.31 | Buy/Sell | $34.00 | 54.76% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$93.00 | Buy/Sell | $85.71 | 7.53% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.28 | Buy/Sell | $17.90 | 94.55% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$11.64 | Buy/Sell | $20.42 | 119.07% |
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
CymaBay Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
CymaBay Therapeutics's EBITDA has seen growth In the last two years, going from $-52.68M to $-92.40M – a gain of 75.40% In the next year, analysts believe that EBITDA will reach $-171.41M – an increase of 85.51%. For the next seven years, the forecast is forEBITDA to grow by 25.02%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$16.71 | Buy/Sell | $33.78 | 79.53% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$22.12 | Buy/Sell | $52.00 | 139.60% |
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$36.30 | Buy/Sell | $63.29 | 112.12% |
CymaBay Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, EBIT for CymaBay Therapeutics has grown by 74.66%, going from $-53.31M to $-93.11M. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach $-148.57M – an increase of 59.56%. In 2030, the professionals' prediction is that CBAY's EBIT will decrease by 891.04%, reaching $736.54M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VCEL Stock Forecast | Vericel | Buy |
8
|
$46.05 | Buy/Sell | $42.58 | 19.44% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.42 | Buy/Sell | $9.94 | 118.07% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.21 | Buy/Sell | $25.00 | 118.55% |
CymaBay Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, CymaBay Therapeutics's EPS has grown by 100.00%, rising from $-0.75 to $0.00. For the next year, analysts predict that EPS will reach $-1.28 – an increase of 100.00%. Over the next seven years, experts believe that CymaBay Therapeutics's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$31.49 | Buy/Sell | $40.00 | 38.14% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.55 | Buy/Sell | $6.00 | 22.14% |
| BCRX Stock Forecast | BioCryst Pharmaceuticals | Outperform |
7
|
$4.16 | Buy/Sell | $14.09 | 152.40% |
.jpg)